Cellerix gains$38M for stem cell work

Three-year-old Cellerix has raised more than €27 million ($38 million) to advance its work on adult stem cell therapies. The Spanish company has a stem cell therapy slated to begin Phase III later this year. Life Sciences Partners and Ventech co-led the round, and were joined by Roche Venture Fund, Novartis Venture Fund and Ysios Capital Partners.

- check out the report from Private Equity Hub

Related Article:
The Top 5 VC deals of the first half of 2007. Report

Suggested Articles

The IPO will push Avidity's lead muscle disorder program through IND-enabling studies and into the clinic in 2021.

Argenx’s phase 3 data set the bar for rival FcRn assets in development at Alexion, Immunovant and UCB.

Tufts scientists discovered that two anti-seizure drugs can lessen the development of brain defects caused by nicotine exposure in frogs.